Literature DB >> 31914003

Impact of Perceived Cardiovascular Risk on Cardiovascular Disease Prevention Behaviors in People With and Without HIV Infection.

Allison Webel1, Christine Horvat Davey1, Julie Schexnayder1, Jackson Currie2, Hamed Al Battashi1, Julia Chang1, Chris T Longenecker1.   

Abstract

BACKGROUND: People living with HIV (PLHIV) are at elevated risk of developing atherosclerotic cardiovascular disease (ASCVD). PLHIV do not engage in recommended levels of ASCVD prevention behaviors, perhaps due to a reduced perception of risk for ASCVD. We examined how HIV status influences knowledge, beliefs, and perception of risk for ASCVD and ASCVD prevention behaviors. METHODS AND
RESULTS: We conducted a mixed-methods study of 191 PLHIV and demographically similar HIV-uninfected adults. Participants completed self-reported surveys on CVD risk perceptions, adherence to CVD medication (aspirin, antihypertensives, and lipid-lowering medication) and 3 dietary intake interviews. All wore an accelerometer to measure physical activity. A subset of PLHIV (n = 38) also completed qualitative focus groups to further examine the influence of HIV on knowledge, perception of risk for ASCVD, and behavior. PARTICIPANTS: They were approximately 54 (±10) years, mostly men (n = 111; 58%), and African American (n = 151, 83%) with an average 10-year risk of an ASCVD event of 10.4 (±8.2)%. PLHIV were less likely to engage in physical activity (44% vs 65%, P < 0.05), and HIV status was associated with 43 fewer minutes of physical activity per week (P = 0.004). Adherence to ASCVD medications was better among PLHIV (P < 0.001). Diet composition was similar between groups (P > 0.05). HIV status did not influence ASCVD risk perceptions (P > 0.05) and modestly influenced physical activity and smoking.
CONCLUSIONS: Although perceptions of ASCVD risk modestly influence some behaviors, additional barriers and insufficient cues to action result in suboptimal physical activity, dietary intake, and smoking rates. However, PLHIV have high adherence to ASCVD medications, which can be harnessed to reduce their high burden of ASCVD.

Entities:  

Mesh:

Year:  2020        PMID: 31914003     DOI: 10.1097/QAI.0000000000002290

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  6 in total

1.  Comparison of diet, muscle strength, steps per day and symptoms in people with HIV and HIV-negative peers.

Authors:  Christine Horvat Davey; Vinh Trinh; Julie Schexnayder; Chris T Longenecker; Allison Webel
Journal:  Res Nurs Health       Date:  2021-12-09       Impact factor: 2.228

2.  Personalized feedback improves cardiovascular risk perception and physical activity levels in persons with HIV: results of a pilot randomized clinical trial.

Authors:  Patricia A Cioe; Jennifer E Merrill; Rebecca E F Gordon; Kate M Guthrie; Matthew Freiberg; David M Williams; Patricia Markham Risica; Christopher W Kahler
Journal:  AIDS Care       Date:  2021-01-23

Review 3.  A Review of Chronic Comorbidities in Adults Living With HIV: State of the Science.

Authors:  Allison R Webel; Julie Schexnayder; Patricia A Cioe; Julie A Zuñiga
Journal:  J Assoc Nurses AIDS Care       Date:  2021 May-Jun 01       Impact factor: 1.809

4.  Perspectives of HIV specialists and cardiologists on the specialty referral process for people living with HIV: a qualitative descriptive study.

Authors:  Charles Muiruri; Amy Corneli; Linda Cooper; Carrie Dombeck; Shamea Gray; Chris T Longenecker; Eric G Meissner; Nwora Lance Okeke; April C Pettit; Teresa Swezey; Joseph Vicini; Gerald S Bloomfield
Journal:  BMC Health Serv Res       Date:  2022-05-09       Impact factor: 2.908

5.  Why Do People Living with HIV Adhere to Antiretroviral Therapy and Not Comorbid Cardiovascular Disease Medications? A Qualitative Inquiry.

Authors:  Charles Muiruri; Isabelle P Sico; Julie Schexnayder; Allison R Webel; Nwora Lance Okeke; Christopher T Longenecker; Juan Marcos Gonzalez; Kelley A Jones; Sarah E Gonzales; Hayden B Bosworth
Journal:  Patient Prefer Adherence       Date:  2020-06-16       Impact factor: 2.711

6.  Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial.

Authors:  Pamela S Douglas; Triin Umbleja; Gerald S Bloomfield; Carl J Fichtenbaum; Markella V Zanni; Edgar T Overton; Kathleen V Fitch; Emma M Kileel; Judith A Aberg; Judith Currier; Craig A Sponseller; Kathleen Melbourne; Anchalee Avihingsanon; Flavio Bustorff; Vicente Estrada; Kiat Ruxrungtham; Maria Saumoy; Ann Marie Navar; Udo Hoffmann; Heather J Ribaudo; Steven Grinspoon
Journal:  Clin Infect Dis       Date:  2021-12-06       Impact factor: 20.999

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.